Conatus Pharmaceuticals Inc (CNAT)

2.26
0.03 1.31
NASDAQ : Health Care
Prev Close 2.29
Open 2.30
Day Low/High 2.21 / 2.32
52 Wk Low/High 1.40 / 7.12
Volume 44.24K
Avg Volume 124.20K
Exchange NASDAQ
Shares Outstanding 21.25M
Market Cap 49.72M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results And Program Updates

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results And Program Updates

Conference Call and Webcast Presentation at 8:00 a.m. ET Today

Conatus Poster At EASL Meeting Today Addresses Safety Of Caspase Inhibition In Cancer Treatment

Conatus Poster At EASL Meeting Today Addresses Safety Of Caspase Inhibition In Cancer Treatment

Late Breaker Oral Presentation Tomorrow to Detail Phase 2 Liver Cirrhosis Trial 3-month Results

FDA Grants Conatus Fast Track Designation For Development Of Emricasan In NASH Cirrhosis

FDA Grants Conatus Fast Track Designation For Development Of Emricasan In NASH Cirrhosis

Focusing on Initial Registration in NASH Cirrhosis With Parallel Development in NASH Fibrosis

Conatus Initiates Phase 2b ENCORE-NF Clinical Trial Of Emricasan In Patients With NASH Fibrosis

Conatus Initiates Phase 2b ENCORE-NF Clinical Trial Of Emricasan In Patients With NASH Fibrosis

Adding Long-term Safety Data to Support Initial Registration of Emricasan in Cirrhosis

Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results

Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results

Conatus Pharmaceuticals (CNAT) stock is increasing in mid-morning trading on Wednesday after the company said a Phase 2 trial of its liver drug showed positive results.

Conatus Pharmaceuticals (CNAT) Stock Spikes on Positive Test Data

Conatus Pharmaceuticals (CNAT) Stock Spikes on Positive Test Data

Conatus Pharmaceuticals (CNAT) shares are up over 10% on strong phase 2 test data of its hypertension treatment candidate.